Cell-Free Circulating Methylated SEPT9 for Noninvasive Diagnosis and Monitoring of Colorectal Cancer

Table 5

Therapeutic efficacy follow-up after curatively intended surgery by mSEPT9 assay.

Number ID	Gender	Age	TNM staging	mSEPT9		CEA		Recurrent status^†
				Pre	Post	Pre	Post
1	Male	74	T3N1bM0	+	−	8.64	1.24	NER
2	Female	68	T3N1aM0	+	−	11.23	3.32	NER
3	Male	72	T2N1aM0	+	+	2.04	1.11	Liver metastases
4	Female	63	T3N0M0	+	−	0.61	0.76	NER
5	Male	54	T2N1aM0	+	−	4.29	1.62	NER
6	Male	56	T3N1bM0	+	−	2.12	1.96	NER
7	Male	56	T4aN2bM0	+	+	2.98	5.21	CNS metastases
8	Female	57	T3N1aM0	+	−	1.88	0.68	NER
9	Female	61	T4aN1aM0	+	−	1.22	1.24	NER
10	Male	53	T4aN1aM0	−	−	1.71	1.42	NER
11	Male	55	T3N0M0	−	−	7.75	2.01	NER
12	Male	63	T3N0M0	+	−	2.32	1.25	NER
13	Male	53	T1N0M0	+	−	4.25	1.89	NER
14	Female	66	T3N0M0	+	−	26.69	1.84	NER
15	Male	77	T3N0M0	+	−	4.12	4.32	NER
16	Female	78	T3N0M0	+	−	2.16	0.82	Unknown
17	Male	82	T3N0M0	+	−	11.08	4.47	NER
18	Male	40	T2N0M0	−	−	1.93	2.12	NER
19	Female	44	T3N0M0	+	−	7.89	0.98	NER

Pre: preoperative; Post: postoperative; NER: no evidence of recurrence; CNS: central nervous system; +: positive; −: negative; boldface in CEA column represents positive; : CRC recurrences or metastases during one-year postoperative follow-up.